Latest total revenue for YS: $570M, below the sector sector average of $1.4B.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2024
Trailing 12 months ending Mar 2024
The latest total revenue for YS is $570M as of March 2024. That is below the sector sector average of $1.4B. Investors often review this figure alongside LakeShore Biopharma Co's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, YS currently prints $570M for total revenue, while the sector average sits near $1.4B. That is roughly 58.8% below the sector mean. Large gaps often invite a closer look at LakeShore Biopharma Co's growth, margins, and balance sheet.
A total revenue figure of $570M for YS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $1.4B. Explore the charts below for those layers of context.
After noting YS's total revenue ($570M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.